GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Medicure MPH.V · CAD

Health Care · TSX Venture · 🇨🇦 Canada

Compare

3.78

+0.80%

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Medicure — daily TSXV:MPH Delayed
Market value
C$39.4m
Last close × shares
Volume
14.2k
Shares, 9 Nov 2026

About Medicure

Its shares trade on TSX Venture under the ticker MPH.V. It has been listed since 30 March 1999. In the fiscal year to 31 December 2025, it reported revenue of C$28.9m and a net loss of C$7.1m. At that date it held total assets of C$24.9m and shareholders' equity of C$12.9m.

Medicure, Inc. is a pharmaceutical company, which engages in the research, clinical development, and commercialization of cardiovascular therapeutics. The company is headquartered in Winnipeg, Manitoba. The firm operates in the biopharmaceutical industry segment. The firm's primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company's United States subsidiary, Medicure Pharma, Inc. AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS). The firm is also engaged in the development of TARDOXAL for neurological disorders, such as Tardive Dyskinesia (TD). The firm has completed Phase IIa stage of development for TARDOXAL. The firm is also developing Transdermal AGGRASTAT, a cure for acute cardiology. Transdermal AGGRASTAT is in preclinical-stage of development.

Figures and description from our data supplier, not checked against the company's own report.

More about Medicure →

Latest on Medicure

Our reporting

We have not reported on Medicure yet.

Next results

19 Nov 2026

Due on 19 Nov 2026. Analysts expect earnings of -0.04 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Medicure's ticker?

Medicure trades as MPH.V on TSX Venture, under ISIN CA58469E4085.

What was Medicure's last closing price?

3.78 on 9 Nov 2026. The figure is in CAD and is never converted.

When does Medicure next report results?

Results are expected on 19 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.